Sensitive HLA antibody testing and the risk of antibody‐mediated rejection and graft failure
HLA · 2024
DOI: 10.1111/tan.15586 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2024. Verfasst von Tim Debyser und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Graft Rejection, Kidney Transplantation, HLA Antigens, Isoantibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Solid phase detection and identification of HLA antibodies in kidney transplantation currently relies on single antigen bead (Luminex®) assays, which is more sensitive than the previously used enzyme‐linked immunosorbent assays (ELISA). To evaluate the impact of more sensitive HLA testing on antibody‐mediated rejection (AMR) occurrence and allograft survival, we analysed 1818 renal allograft recipients transplanted between March 2004 and May 2021. In 2008, solid phase testing switched from ELISA to Luminex. We included 393 (21.6%) transplantations before and 1425 (78.4%) transplantations after transition from ELISA‐ to Luminex‐based testing. For this study, bio‐banked ELISA era samples were tested retrospectively with Luminex. Significantly less pretransplant DSA were found in patients transplanted with pre‐existing HLA antibodies in the Luminex (109/387) versus the ELISA period (43/90) (28% vs. 48%, p < 0.01). Throughout histological follow‐up, 169 of 1818 (9.3%) patients developed AMR. After implementing Luminex‐based testing, the rate of AMR significantly decreased ( p = 0.003). However, incidence of graft failure did not significantly differ between both eras. In conclusion, less patients with pretransplant DSA were transplanted since the implementation of Luminex HLA testing. Transition from ELISA‐ to Luminex‐based HLA testing was associated with a significant decrease in AMR occurrence post‐transplantation. Since the decline of AMR did not translate into improved graft survival, Luminex‐based testing has the added value of preventing low‐risk AMR cases. Therefore, Luminex' high sensitivity must be balanced against waiting time for a suitable organ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium.
- Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross Flanders, Mechelen, Belgium.
- Department of Imaging & Pathology, University Hospitals Leuven, Leuven, Belgium.
- Department of Nephrology and Kidney Transplantation, University Hospitals Leuven, Leuven, Belgium.
- Comprehensive Transplant Center, Northwestern University, Chicago, Illinois, USA.
ORCID-Profile: Tim Debyser, Jasper Callemeyn, Maarten Coemans, Priyanka Koshy, Dirk Kuypers, Aleksandar Senev, Anat R Tambur, Elisabet Van Loon, Karolien Wellekens, Maarten Naesens, Marie-Paule Emonds
Zitieren
APA
Debyser, T., Callemeyn, J., Coemans, M., Kerkhofs, J., Koshy, P., Kuypers, D., Senev, A., Tambur, A. R., Van Loon, E., Wellekens, K., Naesens, M., & Emonds, M. P. (2024). Sensitive HLA antibody testing and the risk of antibody‐mediated rejection and graft failure. HLA. https://doi.org/10.1111/tan.15586
Vancouver
Debyser T, Callemeyn J, Coemans M, Kerkhofs J, Koshy P, Kuypers D, et al. Sensitive HLA antibody testing and the risk of antibody‐mediated rejection and graft failure. HLA. 2024. doi:10.1111/tan.15586
BibTeX
@article{Debyser2024,
author = {Debyser, Tim and Callemeyn, Jasper and Coemans, Maarten and Kerkhofs, Johan and Koshy, Priyanka and Kuypers, Dirk and Senev, Aleksandar and Tambur, Anat R and Van Loon, Elisabet and Wellekens, Karolien and Naesens, Maarten and Emonds, Marie-Paule},
title = {Sensitive HLA antibody testing and the risk of antibody‐mediated rejection and graft failure},
journal = {HLA},
year = {2024},
doi = {10.1111/tan.15586}
}
EUVIMED